Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma

M. Ladetto, F. Zallio, S. Vallet, I. Ricca, A. Cuttica, D. Caracciolo, P. Corradini, M. Astolfi, S. Sametti, F. Volpato, P. Bondesan, U. Vitolo, M. Boccadoro, A. Pileri, A. M. Gianni, C. Tarella

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences